Tobacco’s Merchants of Death
Chewing tobacco and other smokeless products contain roughly 3,000 to 4,000 chemical compounds. At least 28 to 30 of them are known human carcinogens, classified as such by the International Agency for Research on Cancer (IARC). Tobacco-specific nitrosamines (TSNAs) drive much of the oral, esophageal, and pancreatic cancer risk. The rest of the inventory is equally grim.
Heavy metals absorbed from soil, fertilizers, and processing equipment include:
- Lead — a neurotoxin and cardiovascular hazard that accumulates in bone and soft tissue.
- Cadmium — a cumulative kidney toxin linked to renal failure, bone loss, and cancers.
- Arsenic — a Group 1 carcinogen that damages blood vessels and causes skin lesions.
- Nickel — associated with mucosal inflammation and cellular mutations.
- Hexavalent chromium — genotoxic and corrosive to DNA.
- Beryllium — a recognized human carcinogen.
Radioactive elements ride along as well. Phosphorus-rich fertilizers deposit polonium-210 and lead-210 on the leaves. These alpha emitters sit millimeters from jawbone and salivary glands.
Polycyclic aromatic hydrocarbons such as benzo[a]pyrene (one of the most thoroughly studied human carcinogens), chrysene, and benz[a]anthracene add to the mutagenic load. Volatile aldehydes and other toxins compound the damage: formaldehyde (a tissue fixative and carcinogen), acetaldehyde (a co-carcinogen), acrolein (which impairs cellular repair), crotonaldehyde, benzene (a leukemogen), hydrazine, and urethane.
Then come the delivery agents manufacturers deliberately balance for speed and addiction. Nicotine is a potent alkaloid that drives chemical dependency while raising heart rate, constricting blood vessels, and increasing cardiac workload. Ammonium compounds and sodium carbonates raise the product’s pH, converting nicotine into its free-base form for near-instant absorption across the mucosa. Phenols and cresols erode the epithelial barrier so the rest of the chemical load penetrates deeper and faster.
Most people think “tobacco and nicotine.” The reality is a miniature hazardous-materials inventory held against bare mucous membranes: alpha radiation next to bone, heavy metals that accumulate rather than clear cleanly, and engineered chemistry that strips protective cell layers so the dose hits almost like an intravenous injection. Switching from cigarettes to chew does not choose a cleaner alternative. It trades combustion byproducts in the lungs for an intense, localized chemical bath in the mouth and gut.
The Cost in Lives
The mortality numbers remain staggering. Tobacco kills more than 7 million people worldwide each year (WHO figures). Roughly 1.3–1.6 million of those deaths occur in non-smokers exposed to secondhand smoke. In the United States, tobacco accounts for roughly 480,000 deaths annually — about one in five total deaths and the leading cause of preventable death.
Smokeless tobacco specifically contributes an estimated 250,000 to 350,000 deaths per year globally, heavily concentrated in South and Southeast Asia, especially India. Recent analyses put chewing-tobacco-attributable deaths near 251,000 in 2023, driven largely by oral, esophageal, and pharyngeal cancers plus cardiovascular events.
Why Not Just Ban It?
If an engineer introduced a new consumer product tomorrow that contained polonium-210, arsenic, and dozens of carcinogens, chemically hooked users, and killed a substantial fraction of them, regulators would stop it before it reached a warehouse. Tobacco enjoys a different status because of politics, history, and money.
Get Kevin Pauley’s stories in your inbox
Join Medium for free to get updates from this writer.
Outright prohibition of a substance with intense physical dependence tends to create black markets — unregulated products with even less quality control and criminal networks capturing the revenue. Tobacco was already woven into the economic and cultural fabric of North America and Europe long before modern public-health law existed. When Congress gave the FDA authority over tobacco in 2009, it explicitly barred the agency from banning all cigarettes or all smokeless products, or from reducing nicotine to zero.
Governments are also financially entangled. Federal, state, and local excise taxes generate tens of billions annually. The 1998 Master Settlement Agreement requires major companies to pay states billions every year; many states issued bonds backed by those future payments, giving public budgets a stake in continued sales. Instead of prohibition, most jurisdictions pursue attrition: high taxes, indoor and public-use bans, flavor restrictions, age-21 laws, and limits on marketing. The strategy aims to dry up the pipeline of new users so the habit contracts demographically rather than through an overnight ban on chemically dependent adults.
Jobs?
Global employment tied to tobacco runs into the tens of millions, but the great majority is agricultural and informal. Formal manufacturing is highly automated and employs far fewer people.
Estimates place tobacco farming at roughly 15–20 million people worldwide, concentrated in China, India, Brazil, Zimbabwe, Indonesia, Malawi, and Mozambique. Formal industrial manufacturing employs only a few hundred thousand globally; modern machines can produce 20,000 cigarettes per minute. Informal hand-rolling of bidis and similar products employs several million more, largely women in South Asia. Industry advocates sometimes claim figures approaching 100 million by including seasonal labor, retail, and logistics.
In the United States the picture is starker. Tobacco product manufacturing employment has fallen to roughly 11,000–16,000 workers. Automation, declining domestic consumption, and competition from overseas leaf have shrunk the core workforce dramatically. A century ago the work was labor-intensive; today a modern plant runs with a few hundred specialized technicians.
Employment continues to decline through automation, crop-substitution programs encouraged by the WHO Framework Convention on Tobacco Control, and industry consolidation under China’s state monopoly and four major multinationals.
A License to Print Money
From the companies’ perspective the economics are enviable. Operating margins in ordinary consumer packaged goods of 15–20 percent are considered strong. Major tobacco firms routinely post 35–50 percent or higher. Altria has frequently run operating margins in the mid-40s to mid-50s percent range, with gross margins well above 60 percent. Philip Morris International and British American Tobacco sustain global operating margins in the mid-to-high 30s.
Demand is highly inelastic because of chemical dependence. When taxes rise, companies pass them on and often add their own price increases. Even as volumes fall in Western markets, profits and cash flow can continue to climb.
Upstream, the cost of leaf is negligible — often pennies per unit. Contract farming systems in places such as Malawi, Zimbabwe, Mozambique, and parts of India frequently leave smallholders in chronic debt. Human-rights reporting consistently documents child labor and “green tobacco sickness” (acute nicotine poisoning from handling wet leaves). The companies buy cured leaf at commodity prices and own neither the weather risk nor the direct labor liability.
Once the leaf reaches automated factories, unit labor cost approaches zero. There is little need for heavy R&D on standard products, almost no spoilage, and minimal redesign. Nearly all operating profit converts to free cash flow, which is returned to shareholders through high dividends (often 6–9 percent yields) and aggressive buybacks, or redirected into next-generation nicotine products (pouches, heated tobacco, e-cigarettes) that carry similarly high margins.
The model extracts cheap agricultural labor from the developing world, processes it at near-zero manufacturing cost, and relies on chemical dependence to lock in revenue.
Historical Deception and Systemic Harm
Internal documents released through the Master Settlement Agreement and federal litigation show that company scientists knew by the 1950s and 1960s that tobacco was both carcinogenic and addictive. In 1963, Brown & Williamson’s general counsel wrote: “Nicotine is addictive. We are, then, in the business of selling nicotine, an addictive drug…” Public strategy for decades was to manufacture doubt. A 1969 R.J. Reynolds memo stated: “Doubt is our product since it is the best means of competing with the ‘body of fact’ that exists in the mind of the general public.” When “light” and “low-tar” products appeared, companies engineered filters and leaf chemistry — including ammonia and alkalizing agents — to keep free-base nicotine delivery high enough to maintain addiction.
The scale of the money is large. China National Tobacco Corporation alone accounts for roughly 45 percent of global cigarette volume and contributes on the order of $200+ billion annually to Chinese state finances. The major multinationals outside China generate tens of billions in net revenue and operating profit. Governments often collect more per pack in taxes than the companies keep in operating profit — another reason regulation and taxation are preferred to prohibition.
Executives typically do not see themselves as villains. They invoke adult choice, fiduciary duty to shareholders within existing law, and a “harm-reduction” pivot into newer nicotine products while continuing to sell combustibles where regulation is weakest. The system does not require cartoonish malice. Lawyers draft liability shields. Chemists optimize absorption. Brand managers set price points. Index funds collect dividends. Each participant performs a discrete task, insulated from the farmer handling toxic leaves or the surgeon removing a tongue. When an economic machine rewards extraction from physical dependence and isolates decision-makers from the human cost, catastrophic harm becomes an ordinary cost of doing business.
That is the defining feature of the industry: not that it sells a dangerous product — many industries do — but that it engineered addiction, suppressed the truth for decades, and structured itself so that the wreckage remains someone else’s problem.
